The goal of these investments is to increase PPMD’s return on mission by moving potential therapies into the clinic. If these investments result in any financial gains, those funds will be reinvested into our research strategy, supporting the continued advancement of therapies. The goal of this program, like PPMD’s other research strategies, is to get effective and safe therapies to the clinic and then into the hands of our community as quickly as possible.
PPMD Venture Pathways is the venture philanthropy program of PPMD, providing industry investment to accelerate therapeutic development.
Part of PPMD’s core mission is to accelerate research, which includes identifying promising therapeutic strategies and spurring their development and translation into the clinic with hope for approval and access for patients.
Through PPMD Venture Pathways, our investment enables companies to complete critical studies needed to secure significant funding required to advance investigational products to the clinic.
Pathways for Impact
For the past 30 years, PPMD has funded more than $55 million in research to enhance our knowledge of Duchenne and Becker muscular dystrophy. We’ve provided funding for a variety of areas of research from basic research to preclinical work and natural history studies laying the foundation for the tremendous therapeutic development we see in the space today.
Recently, we have watched as more of our academic partners and thought leaders look for ways to expedite their research programs, moving them from bench to bedside. The challenge for many of these groups is generating sufficient data packages to entice significant investors, to make the sizable investments required to take a product through to a human clinical trial. This includes all of the safety, efficacy, and regulatory steps needed.
Advancing Pathways Forward
Recognizing this challenge in the drug development landscape and identifying a gap that PPMD can help fill, we have begun investing in biopharmaceutical companies where we can de-risk and catalyze the development of novel therapies to treat Duchenne and Becker.
We are excited to add this approach to our historically successful research strategy, which we will continue to use to drive our support of critical basic science and natural history studies.
Through this process, we will measure our success by how our investments drive innovative science, disseminate learnings through publication, contribute to the development of IND packages, and push therapies into clinical trials.
To learn more about how you can support PPMD Venture Pathways please reach out to Erin@parentprojectmd.org